The study of the treatment efficacy in prostate cancer with low dose abiraterone

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20211012001

Enrollment

Registered

2021-10-12

Start date

2019-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer Prostate cancer

Interventions

Prostate patients who were treated with Abiraterone 250 mg

Treatment

Low dose Abiraterone

Eligibility

Sex/Gender

Male

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Metastatic prostate cancer patients who are not previously received chemotherapy. 2. Patients agree to consent for the study. 3. ECOG performance status 0-2

Exclusion criteria

Exclusion criteria: 1. Patient who has prior treatment with abiraterone or enzalutamide. 2. Patient who has received treatment with drug or other procedure such as radiation therapy and radionuclear Radium 223 method.

Design outcomes

Primary

Measure	Time frame
Survival time Aug 2019 - July 2020 observational and comparative design	—

Secondary

Measure	Time frame
Progression free survival Aug 2019 - July 2020 observational and comparative design,Quality of life Aug 2019 - July 2020 observational and comparative design,PSA response Aug 2019 - July 2020 observational and comparative design	—

Countries

Thailand

Contacts

Public ContactPhichai Chansriwong

Ramathibodi Hospital

phichaionco103@gmail.com66819145448

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026